LouisDN, SuvaML, BurgerPC, et al.: Chapter 1: Diffuse astrocytoma and oligoendendroglial tumors–Glioblastoma, IDH wildtype. In: LouisDN, OhgakiH, WiestlerOD, et al. (eds): WHO Classification of Tumours of the Central Nervous System, 4th ed. Lyon, France: International Agency for Research on Cancer, 2016, pp. 28–45.
2.
PreusserM, de RibaupierreS, WohrerA, et al.: Current concepts and management of glioblastoma. Ann Neurol, 2011; 70:9–21.
3.
StruppR, HegiME, MasonWP, et al.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of EORTC-NCIC trial. Lancet Oncol, 2009; 10:459–466.
4.
OmuroA, DeAngelisLM: Glioblastoma and other malignant gliomas: A clinical review. JAMA, 2013; 310:1842–1850.
5.
BoeleFW, RooneyAG, GrantR, KleinM: Psychiatric symptoms in glioma patients: From diagnosis to management. Neuropsychiatr Dis Treat, 2015; 11:1413–1420.
6.
FritzL, DirvenL, ReijneveldJC, et al.: Advance care planning in glioblastoma patients. Cancers (Basel), 2016; 8:E102.
ValkoPO, SiddiqueA, LinsenmeierC, et al.: Prevalence and predictors of fatigue in glioblastoma: A prospective study. Neuro Oncol, 2015; 17:274–281.
9.
FranceschiE, MinichilloS, BrandesAA: Pharmacotherapy of glioblastoma: Established treatments and emerging concepts. CNS Drugs, 2017; 31:675–684.
10.
GilbertMR, DignamJJ, ArmstrongTS, et al.: A randomized trial of bevecizumab for newly diagnosed glioblastoma. N Engl J Med, 2014; 370:699–708.
11.
ChinotOL, WickW, MasonW, et al.: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med, 2014; 370:709–722.
12.
MehtaM, WenP, NishikawaR, et al.: Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Review Oncol Hematol, 2017; 111:60–65.
13.
KesselheimJC, NordenAD, WenPY, JoffeS: Discontinuing bevacizumab in patients with glioblastoma: An ethical analysis. Oncologist, 2011; 16:1435–1439.
14.
KuchinadKE, StrowdR, EvansA, et al.: End of life care for glioblastoma patients at a large academic care center. J Neurooncol, 2017; 134:75–81.
15.
ThierK, CalabekB, TinchonA, et al.: The last 10 days of patients with glioblastoma: Assessment of clinical signs and symptoms as well as treatment. Am J Hosp Palliat Care, 2016; 33:985–988.
